Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses - Concepedia

Concepedia

Publication | Open Access

Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses

DOI Full Paper Access

141

Citations

34

References

2019

Year

Taofeek K. Owonikoko, Huifeng Niu, Kristiaan Nackaerts, Tibor Csőszi, Gyula Ostoros, Z. Mark, Christina S. Baik, Anil A. Joy, C. Chouaïd, Jesus Corral Jaime,

Journal of Thoracic Oncology

References

	Year	Citations

Page 1